Development and Characterization of Proteomic Aging Clocks in the Atherosclerosis Risk in Communities (ARIC) Study

Biological age may be estimated by proteomic aging clocks (PACs).

Previous published PACs were constructed either in smaller studies or mainly in White individuals, and they used proteomic measures from only one-time point.

In the Atherosclerosis Risk in Communities (ARIC) study of about 12,000 persons followed for 30 years (around 75% White, 25% Black), we created de novo PACs and compared their performance to published PACs at two different time points.

We measured 4,712 plasma proteins by SomaScan in 11,761 midlife participants, aged 46–70 years (1990–92), and 5,183 late-life pariticpants, aged 66–90 years (2011–13).

All proteins were log2-transformed to correct for skewness.

We created de novo PACs by training them against chronological age using elastic net regression in two-thirds of healthy participants in midlife and late life and compared their performance to three published PACs.

We estimated age acceleration (by regressing each PAC on chronological age) and its change from midlife to late life.

We examined their associations with mortality from all-cause, cardiovascular disease (CVD), cancer, and lower respiratory disease (LRD) using Cox proportional hazards regression in all remaining participants irrespective of health.

The model was adjusted for chronological age, smoking, body mass index (BMI), and other confounders.

The ARIC PACs had a slightly stronger correlation with chronological age than published PACs in healthy participants at each time point.

Associations with mortality were similar for the ARIC and published PACs.

For late-life and midlife age acceleration for the ARIC PACs, respectively, hazard ratios (HRs) per one standard deviation were 1.65 and 1.38 (both p<0.001) for all-cause mortality, 1.37 and 1.20 (both p<0.001) for CVD mortality, 1.21 (p=0.03) and 1.04 (p=0.19) for cancer mortality, and 1.46 and 1.68 (both p<0.001) for LRD mortality.

For the change in age acceleration, HRs for all-cause, CVD, and LRD mortality were comparable to those observed for late-life age acceleration.

The association between the change in age acceleration and cancer mortality was insignificant.

In this prospective study, the ARIC and published PACs were similarly associated with an increased risk of mortality and advanced testing in relation to various age-related conditions in future studies is suggested.